SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Biogen Alzheimer’s Drug Slowed Cognitive Decline 38% After Two Years

New trial data showed the lowest dose of Biogen’s experimental anti-tau drug slowed cognitive decline in early Alzheimer’s patients by 38% after two years.

BIIB

By Deena BeasleyThe lowest dose of Biogen's NASDAQ:BIIB experimental drug that cuts levels of toxic tau protein in the brain slowed cognitive decline in early Alzheimer's patients by 38% after two years, according to new trial data presented on Tuesday.The follow-up data shows that the benefit of t…

Related stories